Abstract: Concerns about the effects of endocrine disruptors on humans and wildlife have resulted in revised governmental testing guidelines (e.g., U.S. Environmental Protection Agency, Organization for Economic Cooperation and Development, U.S. Food and Drug Administration), adding endpoints to enhance their capability to detect endocrine active compounds. Based on experience with these testing guidelines, I present my opinions and data on study design, performance, results, endpoints, interpretation, and recommendations for improvement. New regulatory endpoints must be reproducible, robust, sensitive, relevant, and consistent. These new endpoints are appropriate: anogenital distance, examination of culled pups on postnatal day 4, examination for retained nipples/areolae in preweanling males, weanling necropsy, acquisition of puberty in offspring, prebreed estrous cyclicity, reproductive organ weights and histopathology, and andrology. Endpoints considered not appropriate are ovarian primordial follicle counts, stage of estrus for parental females at demise, and single blood sample at necropsy to measure circulating levels of relevant hormones. In conclusion: (1) regulatory guidelines represent only the minimum requirements and should/will change as science improves and scientific and societal concerns arise; (2) scientists must interact to identify and refine new methods, endpoints, and mechanisms; (3) the objective of these studies is to provide good science and useful information for risk assessment. Regulatory agencies should convene workshops with stakeholders to discuss issues such as new fundamental/applied information, mechanisms, and current and new endpoints. Interactions will lead to enhanced science, periodic revisions of testing guidelines, and improved risk assessment.
STUDY DESIGN
The multigeneration study design is "apical". Intact animals are exposed beginning as postpubescent animals through adulthood and reproduction (F0 generation), beginning as gametes through adulthood and reproduction (F1 generation-the most important generation), and beginning as gametes to weaning (F2 generation). Therefore, a number of critical, sensitive life stages are exposed, including prenatal, perinatal, lactational, prepubescent, peripubescent, adult, and reproductive. Route of administration mimics the route known, anticipated, or modeled for the target species. Doses (or dietary or drinking-water concentrations) are usually selected to include a clear adult effect level (usually exceeding environmental exposure by order[s] of magnitude) to very low environmentally relevant doses. There are many endpoints to detect endocrine-mediated outcomes, from centrally mediated effects (e.g., brain, hypothalamus) to locally mediated effects (e.g., on gonads, sex accessory organs, other glands and organs). As an apical test (and not a "specific" one), it will not necessarily identify the specific mechanism(s), but its design evaluates multiple possible mechanisms. The endpoints chosen become very important (endpoints are discussed in more detail below).
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PERFORMANCE
Staff must be well trained and competence reaffirmed, with intra-and inter-technician variability ascertained and shown to be low. Historical control data from the performing laboratory are also very important to provide context and interpretation for observed effects (e.g., the concurrent control value is very low, but the dose group value is well within the historical control range). The choice of methodologies used to evaluate endpoints is also critical. For example, anogenital distance is measured in some laboratories with a ruler and a hand-held animal, resulting in large variability. In my laboratory, we use an ocular diopter with a stage micrometer attached to a dissecting microscope for newborn anogenital distances. The selection of which instruments will determine the accuracy, with some models accurate to 0.2 mm (when newborn control rat values are typically 2.0 mm for males and 1.0 mm for females) and some accurate to 0.01 mm. This means that differences of 0.2 to 0.3 mm may be statistically significantly different but not necessarily biologically significant. For weanling and adult anogenital distances, my laboratory uses digital vernier calipers (these work best on animals after euthanasia prior to necropsy). Other simple things that may affect the study performance include checking balance calibrations before and after weighing animals and organs, keeping procedures consistent across generations and studies, and documenting clinical observations carefully, completely, and consistently. These studies, typically used for risk assessment by cognizant governmental agencies, are ideally performed in compliance with stringent good laboratory practice (GLP) principles, regulations, and standards. This adherence to GLPs will ensure appropriate procedures and training for the study performance.
ENDPOINTS
It is my thesis that endpoints in this type of study (for risk assessment purposes) must first be shown to be robust, reproducible, appropriately sensitive, biologically plausible, and relevant to the adverse outcomes of concern. Definitions of the attributes of such endpoints are as follows:
1. Reproducible: These endpoints must be reliable: the same findings occur under the same conditions within the initial reporting laboratory (intra-laboratory) and among other laboratories (interlaboratory). If the results from endpoints are not reproducible, they cannot form the basis for future research and are most likely not useful for risk assessment. 2. Robust: These endpoints must be present after comparable routes of exposure (e.g., dosed feed or dosed water). The use of oral gavage, a bolus dose once per day, may result in exacerbation of the effect on an endpoint if the parent material is the proximate toxicant and is metabolized to a nontoxic metabolite, and, if bolus dosing overwhelms the metabolic capacity of the organism or preparation, it may result in diminution or loss of the effect on an endpoint if the parent compound must be metabolized to the active form. Different effects may be observed by non-oral routes, such as inhalation, topical application, and injection, since these routes bypass "first-pass" metabolism by the liver. The findings from routes unrelated to human or environmental exposures may not be useful for risk assessment. These findings must also be present at the same routes and doses over time. 3 . Sensitive: These endpoints should not be dependent on unique conditions (e.g., intrauterine position [IUP]), especially those that are not relevant to the species at risk. These endpoints should not exhibit high variability (insensitive) or be greatly affected by confounders (too sensitive). 4. Relevant: These endpoints must be biologically plausible and related to "adverse" effects of interest/concern. If there are no "adverse" effects at the dose/duration/route evaluated, these endpoints should be predictive of other "adverse" effects at higher doses, after longer exposure duration, and/or by different routes, etc. 5. Consistent: These endpoints must occur in the presence of effects in other related, relevant endpoints, if possible, at the same dose, timing, duration, routes of exposure, etc. [6] . c Linuron [7] . d Testosterone propionate [5] . e At the top dose, external sex distinction could not be made for most offspring; this is the range of AGD values for these pups [5] . f 17ß-trembolone [8] .
tions. We recommend measuring anogenital distance in newborn F1 animals as well, a generation that is thoroughly evaluated through sexual maturity and reproduction. This will enable interpretation of the consequences or predictability, if any, of altered anogenital distance.
Necropsy of culled pups on pnd 4: Neither the OECD nor OPPTS guidelines specify what to do
with the culled pups (standardizing litters is optional in OECD 416). My strong recommendation is to necropsy the culled pups. Testes, epididymides, ovaries, and uteri can be weighed to detect changes in size better than by visual examination alone. Ectopic/undescended testes can be detected, as well as major malformations (e.g., missing parts of epididymides, missing testes and/or epididymides, necrosis, swelling, flaccidity of testes) in these organs. Table 2 , A and C): This is not included in the current guidelines. Involution of fetal nipples in males is DHT-mediated, and retained nipples persist into adulthood. In the author's laboratory, retained nipples have never been observed in control preweanling CD ® (Sprague-Dawley [SD]) male rats, although areolae are present in our laboratory in 0 to 2.7 % of control males on pnd 11-13 (based on examination of over 3000 males in toto). Reduced nipples and/or areolae in female preweanlings are observed when they are exposed in utero to a strong androgen ( Table 2 , B and D). This is a sensitive indicator of altered testosterone (T) and/or DHT levels (e.g., effects on synthesis, degradation, receptor binding, transcriptional activation). Male pups with retained nipples are more likely to exhibit reproductive system malformations, but the correlation is not perfect (i.e., some males with nipples exhibit no malformations, and some males with no nipples do exhibit malformations). It is also a reasonable predictor at lower doses of male reproductive malformations from perinatal exposures at higher doses. Reduction in areolae/nipples in preweanling females was associated with reproductive system abnormalities [6] . In my laboratory, we examine preweanling rat offspring on pnd 11-13 and preweanling mouse offspring on pnd 9-11. Values represent incidence of nipples and/or areolae on pnd 13: * = p < 0.05, ** = p < 0.01, *** = p < 0.001, **** = p < 0.0001. a An antiandrogen (Tyl, unpublished observations). b Bisphenol A [9] . c L = linuron [7] . d Flutamide [6] e Testosterone proprionate [5] . f 17ß-Trenbolone [8] . 4 . Weanling necropsy: As currently specified in both OECD and OPPTS guidelines, limited organ weights (brain, spleen, thymus) are collected from only 1 pup/sex/litter. In the OPPTS guideline, up to 3/sex/litter are necropsied, but organ weights are taken for only 1 pup/sex/litter. In my laboratory, we weigh organs from all 3/sex/litter; it does not increase the power for statistical analysis since the number of litters is the same, but it better characterizes the parameters per litter. We also recommend weighing ovaries, uterus with cervical vagina, testes, epididymides, seminal vesicles, and liver (and possibly kidneys and adrenals), especially if these are possible target organs. 5. Acquisition of puberty (in both sexes; Table 3 ): In females, it is indicated by vaginal opening or patency (VP); in males, it is indicated by preputial separation (PPS; balanopreputial separation). Within one or a few days post VP, the female exhibits her first estrus, so age at first estrus (absolute age and/or interval from VP to first estrus) is also useful. VP is dependent on 17ß-estradiol, and PPS is dependent on testosterone (T). Less useful in males is testes descent (into the scrotal sacs from the abdominal cavity through the inguinal canal and ring), which occurs during lactation (pnd 15-20) and may be mediated by T and/or DHT. In control CD ® (SD) rats in the author's laboratory, the grand mean age at VP is 31.1 days and 41.9 days at PPS (based on 20 studies from 1996 to 2002). Acquisition of puberty in both sexes is affected by body weight, so the current approach is to covary the age at acquisition by the body weight at acquisition (so that pups are at equivalent physiological states, regardless of age), or by an arbitrary calendar date or age, preferably an age that is during the time of acquisition of puberty (so that pups are at equivalent ages, regardless of physiological state). Other suggested body weights as covariates include those at weaning, birth (the last is least useful in the author's opinion; it also requires that the pups are individually identified at birth), or by some measure of weight gain during the postlactational, . e Flutamide [6] . f 100 % of the F1 male offspring at the high dose exhibited hypospadias, so PPS could not be determined [6] . g Testosterone propionate [5] . [5] . TB = 17ß-trenbolone [8] . BPA = bisphenol A [9] . CA = cyproterone acetate. DBP = di-n-butyl phthalate [10] . Fl = flutamide [10] . L = linuron [10] . V = vinclozolin [10] . Fa = fadrazole; aromatase inhibitor [11] . K = ketaconazole; testosterone biosynthesis inhibitor [11] . *, **, *** = p < 0.05, 0.01, 0.001 vs. control group value. SV/CG = seminal vesicles/coagulating glands. ASG = accessory sex glands. LABC = levator ani bulbocavernosus complex. A, D-G = multigeneration studies with exposure in the feed; exposures to F0 animals began at puberty, exposure to F1, F2, and F3 animals began as gametes (F3 animals not bred). B and C = immature castrated male rats were dosed for 8-13 days by subcutaneous injection. H-N = 15-day exposure by oral gavage to adult intact male rats. A = absolute organ weight in grams (g). R = relative organ weight as percentage of terminal body weight.
Retained/reduced nipples and areolae in preweanlings (
7. Gross Necropsy Observations (Fig. 5 as target organs from the list in item 7 above. Systemic organs should not be ignored, as effects on reproduction or development may be mediated by systemic toxicity. 9. Andrology: Includes epididymal (cauda) sperm number, motility (and progressive motility), morphology, and testicular homogenization-resistant spermatid head counts (SHC) to calculate daily sperm production (DSP) and efficiency of DSP. Epididymal sperm motility must be done immediately after demise (within 2 min in the author's laboratory); the other endpoints can be evaluated at a later date. The age of the male at demise is critical. With an average duration of spermatogenesis in rats of approximately 70 days and of epididymal transit time in rats of 10 to 14 days, there are essentially no sperm in the epididymides in a 60-day old rat, very little in the cauda of a 70-day old rat, and close to adult values in rats at and above 85 days of age.
10.
Other: Such as estrous cyclicity (evaluated daily for at least 2 weeks; 3 weeks is better), precoital interval, gestational length, and circulating hormone concentrations (basal and after challenge); the last is best done by longitudinal evaluations (in satellite groups of cannulated rats), etc. 11. Current regulatory guidelines specify selection of one F1 pup/sex/litter at weaning to be retained to adulthood for breeding to generate F2 offspring. Will we miss subtle lesions or effects at low incidence? Should more pups per litter be retained postwean? This will not improve statistical power since that is based on the number of litters/group, but it will improve the characterization and sensitivity of parameters for each litter. This concern is being evaluated under the USEPA EDSP contract.
Examples of inappropriate endpoints (the author's current list) are:
1. Ovarian primordial follicle counts ( Table 5) : As currently done, this endpoint is too "noisy" (insensitive), with large variance terms. Interpretation is also a problem. A better approach would be to quantify all stages of oocyte development: primordial, small antral, large antral, and mature (Graäfian) follicles. This is very labor intensive (and, therefore, expensive), but it provides a complete assessment of oogenesis. Therefore, it should be done (in my opinion) only if other endpoints indicate possible ovarian toxicity (e.g., changes in absolute and relative ovarian weight, total implants per litter). Data presented as mean ± SEM. * = p < 0.05 (in the presence of reduced absolute and relative ovarian weights). C (BPA) = bisphenol A [9] . G (AA) = antiandrogen (Tyl, unpublished observations). A -G is from the author's laboratory.
2.
Stage of estrus at scheduled necropsy (Table 6 ): This is a compromise endpoint; earlier draft versions of the current USEPA OPPTS reproductive toxicity testing guidelines specified that the parental females were all to be necropsied at the same stage of estrus. This endpoint, as currently specified in the finalized guidelines (1998) Experience with new testing guidelines with endocrine-sensitive endpointstified as in transition (e.g., P/E, E/M, M/D) in my laboratory are included in the earlier stage (e.g., P, E, M); otherwise, the statistical analyses are close to impossible. The specified 3-week premating evaluation of estrous cyclicity is much more informative. 
